louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02190032: Modified Angled Tube vs. Conventional Angled Tube in Double-lumen Endotracheal Tube Intubation
Official title: Comparison of Individually Modified Angled Tube and Conventional Angled Tube in Double-lumen Endotracheal Tube Intubation: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intubation, Intratracheal
Thoracic Surgical Procedures
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2014-07-15
Enrollment: 108
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The investigators are trying to compare the individually modified-angled tube and the conventional-angled tube in ease of double lumen endotracheal tube insertion and the incidence of related postoperative complications.

Detailed description: Inserting a double lumen endotracheal tube is somewhat more difficult than a single lumen tube intubation because of its larger outer diameter and the more rigid feature. Moreover, the airway axes (oral-,pharyngeal-, and laryngotracheal axis) are not always straight under sniffing condition. Therefore, to make easy to insert a double-lumen tube and reduce the tube-related complications, we are trying to compare the individually angle-modified tube and the manufacturer-provided-angled tube.

Eligibility criteria: Inclusion Criteria:

* Subjects undergoing thoracic surgery under one lung ventilation
* Subjects older than 20 yrs who can give written informed consent

Exclusion Criteria:

* Those who need rapid sequence intubation
* Those with cervical spinal disease (cervical spinal injury, rheumatoid arthritis with atlantoaxial subluxation)
* Those with oropharyngeal obstructive disease (including tumor, foreign body)
* Those who are expected prolonged intubation after surgery
* Those who are pregnant

Primary outcomes:
measure: The time taken to intubate a double-lumen tube
timeFrame: within 60 sec
Secondary outcomes:
measure: The number of attempts needed for successful intubation
timeFrame: Intubation
measure: The time taken for the first attempt of intubation
timeFrame: within 60 sec
measure: Postoperative sore throat, hoarseness or dysphagia
timeFrame: 30 minutes and 24hours after extubation
Other outcomes:
measure: Hemodynamic change
timeFrame: 1, 3 and 5 min after intubation
measure: Intubation difficulty scale score
timeFrame: At intubation
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Jong Hwan Lee, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Min JJ, Lee JH, Kang SH, Kim E, Lee SM, Cho JH, Kim HK. The Fast and Easy Way for Double-Lumen Tube Intubation: Individual Angle-Modification. PLoS One. 2016 Aug 18;11(8):e0161434. doi: 10.1371/journal.pone.0161434. eCollection 2016.
Clinical trial NCT04591132: Technology-based Analysis of Movement Disorders
Official title: Technology-based Analysis of Movement Disorders
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Movement Disorders
Lead sponsor: University College, London
Sponsor class: OTHER
First posted: 2020-10-19
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Objectives: To generate pilot data to investigate the feasibility and the potential use in clinical practice of technology based objective measures of motor performances in patients affected by different movement disorders. To correlate kinematics findings with demographic and clinical details. Trial design and methods: Participants enrolled in prof. Bhatia's movement disorders clinic, will be classifies according to the main movement disorder, specifically, tremor, parkinsonism, dystonia, chorea, ataxia. In the study visit (one day only), they will undergo a clinical evaluation using the appropriate clinical scales (respectively, Fahn-Tolosa-Marin tremor rating scale, MDS-UPDRS Part III, Toronto Western Spasmodic Torticollis Rating Scale 2, Unified Hungtington Disease Rating scale and Scale for the Assessment and Rating of Ataxia) and a kinematic evaluation, using wearables and an infra-red and LED markers system. Then the protocol is concluded and they will continue the routine clinical follow-up


Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of parkinsonism and/or dystonia and/or tremor due to:

  1. idiopatic parkinson's disease
  2. atypical parkinsonism
  3. sporadic or inherited/genetic dystonia
  4. young-onset Parkinson's disease
  5. Ataxia syndrome
  6. Choereic syndrome
  7. Essential tremor
  8. Dystonic tremor
* 18 to 80 years of age
* Willing and able to provide informed consent
* able to walk unassisted

Exclusion Criteria:

* Change in pharmacological therapy in the last 3 months.
* Participated in a clinical drug trial up to 3 months before inclusion into the present study
* Orthopaedical comorbidities affecting gait or posture.
* Cognitive deficit

Primary outcomes:
measure: gait metrics
timeFrame: up to 6 weeks after enrolment
measure: tremor peak frequence
timeFrame: up to 6 weeks after enrolment
measure: neck ROM
timeFrame: up to 6 weeks after enrolment
measure: bradykinesia evaluation
timeFrame: up to 6 weeks after enrolment
Secondary outcomes:
measure: correlation with UPDRS gait Item
timeFrame: up to 6 weeks after enrolment
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05073432: Development of a Personalized Discussion Prioritization Tool for Older Adults Considering Adjuvant Chemotherapy for Breast Cancer
Official title: A Study in Development of a Personalized Discussion Prioritization Tool for Older Adults Considering Adjuvant Chemotherapy for Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Cancer
Keywords: Breast Cancer
Discussion Prioritization Tool (DPT)
Lead sponsor: University of Rochester
Sponsor class: OTHER
First posted: 2021-10-11
Enrollment: 10
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The investigators have developed a Discussion Prioritization Tool (DPT) for older adults consider adjuvant chemotherapy that utilizes Conjoint Analysis (CA) methodology and the objective of the current study is to assess usability of this DPT in the target population, older adults with breast cancer and to adapt the tool to optimize usability for the target population.

Detailed description: Given the complexity of adjuvant chemotherapy decision making for older adults with breast cancer, enhancing support and promoting treatment discussions in the context of patient's goals and preferences is an important need. With this need in mind, the investigators have completed interviews with patients with cancer patients who are considering adjuvant therapy. As a result of these interviews, the investigators have developed a common list of attributes (variables found to be important in decision making) that were used to create the Discussion Prioritization Tool (DPT) using Conjoint Analysis (CA) methodology. CA which is a method that can assess the relative importance that patients place on different aspects of care by asking patients to make a series of trade-offs between competing options. The purpose of this study is to assess the usability of a Discussion Prioritization Tool, administered through a tablet, laptop, or computer, for its ability to aid in treatment decision-making. The investigators would like to gather feedback from individuals to improve and adapt the communication tool.

Eligibility criteria: Inclusion Criteria:

* Age ≥65
* Diagnosis of stage I-III BC
* Being considered for adjuvant chemotherapy
* Able to speak and read English
* Able to participate in study procedures.

Exclusion Criteria:

* Lacking medical decision-making capacity as determined by their oncologist
* Evidence of metastatic disease

Primary outcomes:
measure: Functional Assessment of the Discussion Prioritization Tool (DPT)
timeFrame: 2 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester
state: New York
Study officials:
affiliation: Univ. of Rochester Wilmot Cancer Center
name: Allison Magnuson, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01107132: Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus
Official title: Blood-retinal Barrier Imaging in Type 2 Diabetes Mellitus: a Window for Blood-brain Barrier Breakdown and Neuropsychiatric Sequela
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Type 2 Diabetes Mellitus
Non-Proliferative Diabetic Retinopathy
Diabetic Macular Edema
Lead sponsor: Soroka University Medical Center
Sponsor class: OTHER
First posted: 2010-04-20
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Sampling method: PROBABILITY_SAMPLE
Study population: Type 2 Diabetes Mellitus Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema

Brief summary: In Type 2 Diabetes mellitus patients we will:

1. quantify vasculopathy and blood-retinal barrier (BRB) leakage
2. measure blood-brain barrier (BBB) permeability and neuroanatomical changes
3. correlate BRB pathology with BBB breakdown, inflammatory markers and neuropsychiatric sequela


Eligibility criteria: Inclusion criteria:

1. T2DM Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME) who are in the clinical database of the ophthalmologic department , above 18 years old at the time of diagnosis and underwent FA examination in the past three years
2. Patients which their medical records are available via a computerized data base

Control group:

1. T2DM patients who are in the clinical database of the ophthalmologic department
2. Above 18 years old at the time of diagnosis
3. Underwent FA examination in the past three years and their examination was interpreted as "normal", i.e. without suspected diabetic retinopathy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Beer-Sheva
country: Israel
facility: Soroka University Medical Center
Study officials:
affiliation: Soroka University Medical Center
name: Hadar Shalev, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00757432: Recovery After Robotic Urogynecological Surgery: The Patient's Perspective
Official title: Recovery After Robotic Urogynecological Surgery: The Patient's Perspective
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urogynecology
Lead sponsor: University of Rochester
Sponsor class: OTHER
First posted: 2008-09-23
Enrollment: 22
Sex: FEMALE
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women who underwent DaVinci-assisted laparoscopic surgery

Brief summary: The purpose of the study is to describe the patient experience, including pain scores, use of pain medications, resumption of usual activities, and bowel function in the post-operative period following robotic urogynecologic surgery. Additionally, to describe peri-operative parameters of robot-assisted urogynecologic surgery.


Eligibility criteria: Inclusion Criteria:

* Women who underwent DaVinci-assisted laparoscopic surgery
* Completion of a post-operative quality assurance questionnaire from 09/2007 - 09/2008

Exclusion Criteria:

* Any women not meeting above inclusion criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester
state: New York
Study officials:
affiliation: University of Rochester
name: Gunhilde Buchsbaum, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05056532: Evaluation of Respiratory Muscle in Patient With Pulmonary Arterial Hypertension
Official title: Evaluation of Primary and Accessory Respiratory Muscles and Their Influence on Exercise Capacity and Dyspnea in Pulmonary Arterial Hypertension
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pulmonary Artery Hypertension
Keywords: respiratory muscle strength
exercise capacity
dyspnea
accessory respiratory muscle
Lead sponsor: Giresun University
Sponsor class: OTHER
First posted: 2021-09-24
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patient group will be chosen among the admitted to clinic control group will consist of invited volunteers

Brief summary: The aim of the study is that evaluation of basic and accessory respiratory muscles and their relationship of six minute walk test in patient with pulmonary arterial hypertension (PAH)


Eligibility criteria: Inclusion Criteria:

* patients with diagnosis of pulmonary arterial hypertension
* patients with stabil drug therapy at least three months

Exclusion Criteria:

* patients with obstructive and/ or restrictive lung disease comorbidity
* severe orthopedic and/ or neurological comorbidity
* patients with heart failure
* patients with ischemic heart disease
* uncooperative patients

Primary outcomes:
measure: pectoralis muscle strength
timeFrame: 15 minute
measure: serratus anterior muscle strength
timeFrame: 15 minutes
measure: sternocleidomasteoideus muscle strength
timeFrame: 15 minutes
measure: Respiratory mouth pressure
timeFrame: 15 minutes
Secondary outcomes:
measure: Six Minute Walk Test (6MWT)
timeFrame: 30 minutes
measure: Dyspnea assessment
timeFrame: 20 minutes
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul university-cerrahpasa cardiology institute
state: Haseki
Study officials:
affiliation: Giresun University
name: Habibe DURDU
role: PRINCIPAL_INVESTIGATOR
References:
citation: Panagiotou M, Peacock AJ, Johnson MK. Respiratory and limb muscle dysfunction in pulmonary arterial hypertension: a role for exercise training? Pulm Circ. 2015 Sep;5(3):424-34. doi: 10.1086/682431.
citation: Riou M, Pizzimenti M, Enache I, Charloux A, Canuet M, Andres E, Talha S, Meyer A, Geny B. Skeletal and Respiratory Muscle Dysfunctions in Pulmonary Arterial Hypertension. J Clin Med. 2020 Feb 3;9(2):410. doi: 10.3390/jcm9020410.
Clinical trial NCT03523832: Preemptive Analgesia in Total Knee Arthroplasty
Official title: Preemptive Analgesia in Total Knee Arthroplasty: Comparing the Effects of Single Dose Combined Celecoxib With Pregabaline and Repetition Dose Combined Celecoxib With Pregabaline (Double Blind Controlled Clinical Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Pain
Lead sponsor: Fakultas Kedokteran Universitas Indonesia
Sponsor class: OTHER
First posted: 2018-05-14
Enrollment: 30
Sex: ALL
Minimum age (years): 55
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Acute Pain is the most common early complication after total knee arthroplasty that caused delayed mobilization, demands of morphine, and higher operative cost. There were many researches that had been done in analgesia method to find the most effective analgesia, lowest side effect, and easy to apply. Preemptive analgesia of combined celecoxib and pregabalin were reported to give a promising outcome.

In a randomized, double blind controlled clinical trial, 30 subjects underwent surgery for total knee arthroplasty using 15-20mg bupivacaine 5% epidural anesthesia. All subjects were divided into three groups. First group was given celecoxib 400mg and pregabaline 150mg 1 hour before operation, second group was given celecoxib 200mg and pregabaline 75mg twice daily started from 3 days before operation, and the last group was given placebo. The outcome was measured with VAS, knee ROM, and post-operative mobilization


Eligibility criteria: Inclusion Criteria:

* 55-80 years old patients who come to orthopaedic polyclinic
* underwent TKA procedure
* have osteoarthritis
* consumed pain killer and anti inflamatory drugs routinely

Exclusion Criteria:

* psychiatric disorder
* have history of renal disease
* histroy of chronic neurophatic
* have genu arthritis that caused by rheumatid arthritis and infection
* diabetic and obesity
* coagulopathy
* patients with severe pain that needed immediate analgesia regimen

Primary outcomes:
measure: Total Morphine Consumption
timeFrame: Third day post-operative
Secondary outcomes:
measure: Post-operative Pain
timeFrame: every morning [daily], up to 3 days
measure: Knee functional outcome
timeFrame: every morning [daily], up to 3 days
measure: Mobilization
timeFrame: on the first day, standing on the second day, and walking on the third day
Other outcomes:
Locations:
Study officials:
References:
citation: Lubis AMT, Rawung RBV, Tantri AR. Preemptive Analgesia in Total Knee Arthroplasty: Comparing the Effects of Single Dose Combining Celecoxib with Pregabalin and Repetition Dose Combining Celecoxib with Pregabalin: Double-Blind Controlled Clinical Trial. Pain Res Treat. 2018 Aug 7;2018:3807217. doi: 10.1155/2018/3807217. eCollection 2018.
Clinical trial NCT02736032: Cryopreserved-thawed Embryo Transfer With or Without Gonadotropin Releasing Hormone Agonist
Official title: Cryopreserved-thawed Embryo Transfer in Down or Non-down Regulated Hormonally Controlled Cycles: a Prospective, Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Infertility
Lead sponsor: Cairo University
Sponsor class: OTHER
Collaborators: name: Nile Ivf Center, Cairo, Egypt
name: Kamal Shaeer center of infertility
First posted: 2016-04-13
Enrollment: 310
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Traditionally, the use of GnRH-a suppression was considered essential for adequate endometrial hormonal modulation in cryopreserved-thawed embryo transfer cycles. Several studies, however, have questioned its necessity for controlled endometrial preparation. Using a high dose of estradiol from day 1 of the cycle will suppress the gonadotroph, preventing folliculogenesis and excessive secretion of LH, allowing adequate endometrial preparation without GnRH-a.


Eligibility criteria: Inclusion Criteria:

* 20-35 years
* BMI 20-30
* Regular menses.
* No PCOS, no endometriosis
* No uterine anomalies or lesions
* No severe male factor
* All grade 1 cleaved stage embryos

Exclusion Criteria:

* Less than 20 or more than 35 years
* BMI less than 20 or more than 30
* Irregular cycles
* PCOS or endometriosis
* Uterine anomalies or lesions
* Severe male factor
* Poor quality embryos for transfer
* Severe

Primary outcomes:
measure: Clinical pregnancy rate
timeFrame: 5 weeks after embryo transfer]
measure: Live birth rate
timeFrame: 9 months
Secondary outcomes:
measure: Estradiol and Progesterone levels on day of start of progesterone supplementation
timeFrame: 12 to 20 days
measure: Endometrial thickness on day of start of progesterone supplementation
timeFrame: 12 to 20 days
measure: Number of days needed for adequate (> 8mm) endometrial thickness
timeFrame: 12 to 20 days
measure: Cycle cancellation: not related to thawing, thin endometrium, high P. OR related to embryos not surviving thawing.
timeFrame: 12 to 20 days
measure: Chemical pregnancy rate
timeFrame: 14 days after embryo transfer
measure: Implantation rate.
timeFrame: 5 weeks after embryo transfer
measure: Early miscarriage rate
timeFrame: 3 months
measure: Ongoing pregnancy rate
timeFrame: 3 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini)
city: Giza
country: Egypt
facility: Kamal Shaeer center of infertility
city: Giza
country: Egypt
facility: Nile IVF center
Study officials:
affiliation: Cairo University
name: Eman K Shaeer, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05181332: Predictive Models of Hepatic Decompensation and Survival Outcomes in Pediatric Patients With Cirrhosis
Official title: Predictive Models of Hepatic Decompensation and Survival Outcomes in Pediatric Patients With Cirrhosis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cirrhosis
Biliary Atresia
Choledochal Cyst
Primary Sclerosing Cholangitis
HBV
HCV
Autoimmune Hepatitis
Lead sponsor: West China Hospital
Sponsor class: OTHER
First posted: 2022-01-06
Enrollment: 400
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric patients with cirrhosis who were diagnosed histologically with definite pathologic specimens.

Brief summary: The aim of this study was to developed and validated models to predict hepatic decompensation and survivals in pediatric patients with cirrhosis and compared these models with currently available models.

Detailed description: Noninvasive liver fibrosis tests such as the NAFLD fibrosis score (NFS), Hepascore, and transient elastography were specifically developed to predict fibrosis and can help predict patients with NAFLD at the highest risk of developing liver-related complications. These tests have been widely applied in adult cirrhosis. The accuracy of these models, however, may be influenced by patient factors including age, body mass index, and diabetes, potentially limiting their prognostic accuracy and clinical practicability in children. Therefore, it is currently unknown how to best predict hepatic decompensation and survival outcomes among pediatric patients with cirrhosis. To fill this knowledge gap, the investigators performed a retrospective-prospective cohort study with the aim of developing and validating a clinical model to predict liver-related complications and survival outcomes in pediatric patients with biopsy-proven with cirrhosis. Secondly, the investigators aimed to compare the predictive accuracy with currently available noninvasive model.

Eligibility criteria: Inclusion Criteria:

* Age up to 18 years old
* No previous episodes of clinical decompensation
* With written informed consent

Exclusion Criteria:

* Clinical data missing
* Without written informed consent

Primary outcomes:
measure: Hepatic decompensation
timeFrame: At least 5-year follow up
Secondary outcomes:
measure: Overall survival
timeFrame: At least 5-year follow up
Other outcomes:
Locations:
city: Chengdu
country: China
facility: West China Hospital, Sichuan University
state: Sichuan
Study officials:
References: